WHO ICTRP trial
Clinical management of relapsed and refractory AML
ChiCTR1900023976 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR1900023976 |
|---|---|
| Public title | Clinical management of relapsed and refractory AML |
| Scientific title | Study on the construction of a targeted drug delivery system for leukemia mediated by tumor cell membrane particles and the influence factors of drug resistance |
| Primary sponsor | Sichuan People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Phase | 4 |
| Countries | China |
| Conditions | Acute myeloid leukemia |
| Interventions | Age under 60:GCSF 300ug d0-d5, Cladribine 5mg/m2, d1-5, cytarabine 2g/m2 qd, d1-5, homoharringtonine 2mg/m2d1-d5.;Age over 60:GCSF 300ug d0-d5, azacytidine 100mg, d1-5, cedarabine 10mg qd, d1-28, cytarabine 10mg/m2 q12h, d3-9… |
| Registration date | Jun 20, 2019 |
| Target size | Age under 60:20;Age over 60:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: